In an atherosclerosis model, pharmacologic inhibition of BRCC3 or genetic deletion of the BRCC3 cofactor ABRO1 in immune cells reduced lesion area, inflammasome activation markers, and NETosis. The gene discussed is BRCC3; the disease is atherosclerosis.